There are fast-track designations for important research, such as a successful potentially pivotal P3 trial. It took only a couple of weeks for the Lecanemab study to be published in NEJM. It is all down to Missling and his co-authors on how fast they can prepare the article and the data in a clear format for submission. I would not urge them to hurry though, we saw what happens when they work with tight deadlines.
It would take too long, the data should speak for itself. But it's still a good idea to have this so that the science can be properly catalogued and communicated for present and future scientists.
News 
Market Data 
Discover 
